Cmed, an oncology focused, innovative technology-led CRO, today announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual Meeting, taking place 9-12 December in Atlanta, GA.
As a full-service CRO, Cmed has a strong reputation in delivering complex and demanding clinical trials across numerous oncology types, including various haematological indications, immuno-oncology, breast, lung, prostate and colorectal. Cmed has combined this deep understanding of the needs of oncology studies with its encapsia clinical data suite, allowing the company to work with sponsors to set-up and conduct trials smarter and more efficiently.
David Connelly, Chief Executive Officer, Cmed, commented: “At Cmed, with 16 years’ experience in oncology clinical trials, we truly understand the importance and practical challenges of conducting oncology clinical studies”
“During these pivotal meetings, we are excited to be able to showcase our encapsia clinical data suite and demonstrate to sponsors the benefits of immediate access to real-time clinical data with live, actionable insights and analytics. These include helping to enroll patients more accurately while bringing improvements to monitoring patient safety, generating high quality data and driving more timely decision-making.”
Visitors are invited to join Cmed at booth #15 during Clinical Operations in Oncology Trials Europe and booth #512 during the ASH Annual Meeting. To schedule a meeting with the Cmed team, please contact email@example.com.